Integration of Immuno-Nutritional Status into International Federation of Gynecology and Obstetrics Risk Stratification to Predict Chemotherapy Response and Survival in Gestational Trophoblastic Neoplasia

International Journal of Gynecological Cancer · Published 2026-07-01 · DOI 10.1016/j.ijgc.2026.104885

Authors (13)

Katia Roque, Rossana Ruiz, Marco Galvez-Nino, Melanie Castro-Mollo, Heberth Daniel Vallejos, Iris Otoya, Yomali Ferreyra, Ofelia Coanqui, Mivael Olivera Hurtado de Mendoza, Natalia Valdiviezo, Henry Leonidas Gomez, Ramon Andrade de Mello, Luis Mas

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Roque, K., Ruiz, R., Galvez-Nino, M., et al. (2026). Integration of Immuno-Nutritional Status into International Federation of Gynecology and Obstetrics Risk Stratification to Predict Chemotherapy Response and Survival in Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2026.104885

Related articles

• Beyond p53 status: the continued importance of histopathologic features for predicting lymph node metastasis in endometrial cancer · International Journal of Gynecological Cancer · 2026 · Same journal
• From intensification to selection: the next challenge in advanced or recurrent endometrial cancer · International Journal of Gynecological Cancer · 2026 · Same journal
• Pre-operative Nutritional Risk Screening 2002-based nomograms for predicting post-operative complications after cytoreductive surgery for ovarian cancer: a multi-center retrospective cohort study · International Journal of Gynecological Cancer · 2026 · Same journal
• Giant vulvar plexiform neurofibroma in neurofibromatosis type 1 · International Journal of Gynecological Cancer · 2026 · Same journal
• Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study) · International Journal of Gynecological Cancer · 2026 · Same journal
• Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study · International Journal of Gynecological Cancer · 2026 · Same journal
• Association between pembrolizumab-based therapy exposure and survival outcomes in metastatic or recurrent uterine carcinosarcoma: a multicenter real-world study · International Journal of Gynecological Cancer · 2026 · Same journal
• Recognizing confounders for the use and outcome associated with intrauterine manipulator during endometrial cancer surgery: a call for research · International Journal of Gynecological Cancer · 2026 · Same journal
• External Validation of the IOTA Two-Step Strategy for Pre-operative Characterization of Adnexal Masses: Comparison with ADNEX, O-RADS and a Sequential Simple Rules–ADNEX Approach · International Journal of Gynecological Cancer · 2026 · Same journal
• Response to correspondence on Differences in First-Line Chemosensitivity Assessed by KELIM in Advanced Serous Ovarian Cancer: Evidence From Western and Japanese Trials in a Gynecologic Cancer InterGroup (GCIG) Meta-analysis · International Journal of Gynecological Cancer · 2026 · Same journal